We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| ALK Abello AS | TG:4AJ0 | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.300001 | -1.47% | 20.06 | 19.97 | 20.16 | 0.00 | 22:50:06 |
From May 2024 to Jul 2024
ALK (ALKB:DC / OMX: ALK B / AKBLF) will host a Capital Markets Day on 4 June at 13.00-17.00.
We cordially invite investors, analysts, and other interested stakeholders to listen in on our Capital Markets Day 2024, where we will share highlights from our strategy review and elaborate on key priorities and value drivers.
During the day, members of ALK’s Leadership team will cover a number of topics including global leadership in respiratory allergy, key markets and growth drivers, R&D, and ALK’s manufacturing processes and capabilities.
The speakers are as follows:
13.00 CEO keynote Peter Halling, President & CEO
13.30 Key MarketsSøren Niegel, EVP Commercial OperationsJacob Glenting, SVP Global Marketing, Partner Markets & ChinaFlora Beiche-Scholz, SVP Region Europe
15.00 R&D Henriette Mersebach, EVP R&DPeter Sejer Andersen, SVP Research & Drug Discovery
15.40 Product SupplyChristian G. Houghton, EVP Product Supply
16.15 FinancialsClaus Steensen Sølje, EVP and CFO
Please see the attached file for a detailed program.
The Capital Markets Day will be webcasted live and will also be available for replay on ALK’s website: https://ir.alk.net/cmd-2024. The presentation slides will be available same place before the meeting starts.
Institutional investors are also welcome to participate in person. Please contact Per Plotnikof, if you have not signed up already.
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Maiken Riise Andersen, tel. +45 5054 1434
About ALKALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.
Attachment
1 Year ALK Abello AS Chart |
1 Month ALK Abello AS Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
